A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients - PubMed (original) (raw)
Meta-Analysis
. 2017 Feb;19(2):216-227.
doi: 10.1111/dom.12804. Epub 2016 Nov 29.
Affiliations
- PMID: 27717195
- DOI: 10.1111/dom.12804
Meta-Analysis
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
Mirna S Abd El Aziz et al. Diabetes Obes Metab. 2017 Feb.
Abstract
Aims: To study differences in clinical outcomes between initiating glucagon-like peptide-1 receptor agonist (GLP-1 RAs) vs insulin treatment in patients with type 2 diabetes treated with oral glucose-lowering medications (OGLM).
Methods: Prospective, randomized trials comparing GLP-1 RA and insulin treatment head-to-head as add-on to OGLM were identified (PubMed). Differences from baseline values were compared for HbA1c, fasting plasma glucose, bodyweight, blood pressure, heartrate and lipoproteins. Proportions of patients reporting hypoglycaemic episodes were compared.
Results: Of 712 publications identified, 23 describing 19 clinical trials were included in the meta-analysis. Compared to insulin, GLP-1 RAs reduced HbA1c more effectively (Δ -.12%, P < .0001). Basal insulin was more effective in reducing fasting plasma glucose (Δ -1.8 mmol/L, P < .0001). GLP-1 RAs reduced bodyweight more effectively (Δ -3.71 kg; P < .0001). The proportion of patients experiencing hypoglycaemic episodes was 34% lower with GLP-1 RAs ( P < .0001), with a similar trend for severe hypoglycaemia. Systolic blood pressure was lower and heartrate was higher with GLP-1 RAs ( P < .0001). Triglycerides and LDL cholesterol were significantly lower with GLP-1 RAs. Long-acting GLP-1 RAs were better than short-acting GLP-1 RAs in reducing HbA1c and fasting glucose, but were similar regarding bodyweight.
Conclusions: Slightly better glycaemic control can be achieved by adding GLP-1 RAs to OGLM as compared to insulin treatment, with added benefits regarding bodyweight, hypoglycaemia, blood pressure and lipoproteins. These differences are in contrast to the fact that insulin is prescribed far more often than GLP-1 RAs.
Keywords: GLP-1 receptor agonists; basal insulin; bodyweight; incretin-based glucose-lowering medications; lipoproteins; meta-analysis; type 2 diabetes.
© 2016 John Wiley & Sons Ltd.
Comment in
Similar articles
- Glucagon-like peptide-1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta-analysis.
Singh S, Wright EE Jr, Kwan AY, Thompson JC, Syed IA, Korol EE, Waser NA, Yu MB, Juneja R. Singh S, et al. Diabetes Obes Metab. 2017 Feb;19(2):228-238. doi: 10.1111/dom.12805. Epub 2016 Dec 5. Diabetes Obes Metab. 2017. PMID: 27717130 Free PMC article. Review. - Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Htike ZZ, et al. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. Diabetes Obes Metab. 2017. PMID: 27981757 Review. - Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA, Meier JJ, Nauck MA. Huthmacher JA, et al. Diabetes Care. 2020 Sep;43(9):2303-2312. doi: 10.2337/dc20-0498. Diabetes Care. 2020. PMID: 32910778 - The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K. de Boer SA, et al. Int J Clin Pharm. 2016 Feb;38(1):144-51. doi: 10.1007/s11096-015-0219-8. Epub 2015 Nov 23. Int J Clin Pharm. 2016. PMID: 26597956 Free PMC article.
Cited by
- The Potential Mechanism of Remission in Type 2 Diabetes Mellitus After Vertical Sleeve Gastrectomy.
Wang R, Mijiti S, Xu Q, Liu Y, Deng C, Huang J, Yasheng A, Tian Y, Cao Y, Su Y. Wang R, et al. Obes Surg. 2024 Aug;34(8):3071-3083. doi: 10.1007/s11695-024-07378-z. Epub 2024 Jul 1. Obes Surg. 2024. PMID: 38951388 Review. - Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.
Son JW, Lim S. Son JW, et al. Endocrinol Metab (Seoul). 2024 Apr;39(2):206-221. doi: 10.3803/EnM.2024.1940. Epub 2024 Apr 16. Endocrinol Metab (Seoul). 2024. PMID: 38626909 Free PMC article. Review. - 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.
American Diabetes Association Professional Practice Committee. American Diabetes Association Professional Practice Committee. Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-S178. doi: 10.2337/dc24-S009. Diabetes Care. 2024. PMID: 38078590 Review. - Overview of meta-analysis.
Fang X, Zhao N, Zhu ZQ. Fang X, et al. Ibrain. 2021 Mar 28;7(1):52-56. doi: 10.1002/j.2769-2795.2021.tb00065.x. eCollection 2021 Mar. Ibrain. 2021. PMID: 37786869 Free PMC article. Review. - Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.
Hoog M, Paczkowski R, Huang A, Halpern R, Buysman E, Stackland S, Zhang Y, Wangia-Dixon R. Hoog M, et al. Diabetes Ther. 2023 Nov;14(11):1947-1958. doi: 10.1007/s13300-023-01473-7. Epub 2023 Sep 23. Diabetes Ther. 2023. PMID: 37740872 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical